SAN DIEGO and SUZHOU, China, Dec 14 (Bernama-GLOBE NEWSWIRE) — Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a biopharmaceutical company committed to transforming the discovery and development of novel antibody-based immunotherapies, today announced preclinical data demonstrating the compelling differentiation of ADG153, an anti-CD47 monoclonal antibody (mAb), and ADG152, a CD20xCD3 bispecific T-cell engager (TCE). The data were presented in two poster presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition taking place December 11-14, 2021, which are available in the Publications section of the company’s website at www.adagene.com.
http://mrem.bernama.com/viewsm.php?idm=41919
- US issues ‘worldwide caution’ for Americans over Mideast conflict
- Iranian President Warns U.S. Of Retaliation After Strikes On Nuclear Sites
- Iraqi Top Leaders Voice Concern Over U.S. Airstrikes On Iran
- Morocco: Thousands rally in capital Rabat to support Palestine
- Philippines Voices Great Concerns Over Escalating Middle East Conflict
- Cambodia Bans Fuel, Gas Imports From Thailand From Sunday Midnight
- Pakistani PM, Iranian President Held Phone Talks Over U.S. Attacks
- Iranian President Slams U.S. Attacks On Nuclear Facilities
- Around 10,000 Afghan Refugees Return From Iran Daily To Escape War
- Trump Says U.S. Attacked Three Iranian Nuclear Sites